Calidi Biotherapeutics Inc
CLDI0.602USD
+0.011+1.91%
Market hours （ET）Quotes delayed by 15 min
19.13MMarket Cap
LossP/E TTM
More Details of Calidi Biotherapeutics Inc Company
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.
Company Info
Ticker SymbolCLDI
Company nameCalidi Biotherapeutics Inc
IPO dateSep 10, 2021
CEODr. Eric Poma, Ph.D.
Number of employees28
Security typeOrdinary Share
Fiscal year-endSep 10
Address4475 Executive Drive, Suite 200
CitySAN DIEGO
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code92121
Phone18587949600
Websitehttps://www.calidibio.com/
Ticker SymbolCLDI
IPO dateSep 10, 2021
CEODr. Eric Poma, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Scott Leftwich
Mr. Scott Leftwich
Independent Director
Independent Director
259.54K
--
Mr. James A. Schoeneck
Mr. James A. Schoeneck
Independent Chairman of the Board
Independent Chairman of the Board
114.13K
--
Mr. Alan R. Stewart
Mr. Alan R. Stewart
Independent Director
Independent Director
28.98K
--
Ms. Wendy Pizarro Campbell, Esq.
Ms. Wendy Pizarro Campbell, Esq.
Chief Administrative Officer, Chief Legal Officer, Chief Diversity Officer, Corporate Secretary
Chief Administrative Officer, Chief Legal Officer, Chief Diversity Officer, Corporate Secretary
--
--
Mr. Allan J. Camaisa
Mr. Allan J. Camaisa
Independent Director
Independent Director
--
--
Col. (Retd.) George E. Peoples, Jr., M.D.
Col. (Retd.) George E. Peoples, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. Stephen Jasper
Mr. Stephen Jasper
Investor Relations
Investor Relations
--
--
Dr. Eric Poma, Ph.D.
Dr. Eric Poma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Travis Clifton, M.D.
Dr. Travis Clifton, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew C. Jackson
Mr. Andrew C. Jackson
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Mr. Scott Leftwich
Mr. Scott Leftwich
Independent Director
Independent Director
259.54K
--
Mr. James A. Schoeneck
Mr. James A. Schoeneck
Independent Chairman of the Board
Independent Chairman of the Board
114.13K
--
Mr. Alan R. Stewart
Mr. Alan R. Stewart
Independent Director
Independent Director
28.98K
--
Ms. Wendy Pizarro Campbell, Esq.
Ms. Wendy Pizarro Campbell, Esq.
Chief Administrative Officer, Chief Legal Officer, Chief Diversity Officer, Corporate Secretary
Chief Administrative Officer, Chief Legal Officer, Chief Diversity Officer, Corporate Secretary
--
--
Mr. Allan J. Camaisa
Mr. Allan J. Camaisa
Independent Director
Independent Director
--
--
Col. (Retd.) George E. Peoples, Jr., M.D.
Col. (Retd.) George E. Peoples, Jr., M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
9.62%
Jamir Trust
1.76%
BMO Nesbitt Burns Inc.
1.42%
Kessler (Judd S)
1.08%
The Vanguard Group, Inc.
1.02%
Other
85.09%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
9.62%
Jamir Trust
1.76%
BMO Nesbitt Burns Inc.
1.42%
Kessler (Judd S)
1.08%
The Vanguard Group, Inc.
1.02%
Other
85.09%
Shareholder Types
Shareholders
Proportion
Hedge Fund
9.77%
Investment Advisor
4.03%
Individual Investor
2.85%
Corporation
2.58%
Investment Advisor/Hedge Fund
1.87%
Research Firm
0.16%
Venture Capital
0.05%
Other
78.69%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
100
7.64M
29.37%
+4.42M
2025Q1
104
7.65M
23.70%
+4.58M
2024Q4
102
3.31M
11.93%
+1.13M
2024Q3
94
2.46M
23.73%
+462.38K
2024Q2
111
2.30M
38.69%
-356.37K
2024Q1
113
2.02M
47.34%
-720.95K
2023Q4
108
2.00M
46.75%
-874.01K
2023Q3
95
1.86M
60.12%
+4.51K
2023Q2
68
377.00K
91.33%
-1.38M
2023Q1
66
400.63K
97.05%
-1.31M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
3.32M
10.45%
+3.32M
--
Mar 31, 2025
Jamir Trust
608.38K
1.91%
--
--
Jun 20, 2025
BMO Nesbitt Burns Inc.
489.80K
1.54%
+477.30K
+3818.40%
Mar 31, 2025
Kessler (Judd S)
372.98K
1.17%
+372.98K
--
May 01, 2024
The Vanguard Group, Inc.
353.38K
1.11%
+292.01K
+475.78%
Mar 31, 2025
AJC Capital LLC
281.51K
0.89%
--
--
Jun 20, 2025
Leftwich (Scott)
259.54K
0.82%
--
--
Jun 20, 2025
Geode Capital Management, L.L.C.
251.92K
0.79%
+91.90K
+57.43%
Mar 31, 2025
Belpointe Asset Management LLC
249.83K
0.79%
+249.83K
--
Mar 31, 2025
Hightower Advisors, LLC
119.47K
0.38%
+17.20K
+16.81%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 05, 2024
Merger
10<1
Jul 05, 2024
Merger
10<1
Jul 05, 2024
Merger
10<1
Jul 05, 2024
Merger
10<1
Date
Type
Ratio
Jul 05, 2024
Merger
10<1
Jul 05, 2024
Merger
10<1
Jul 05, 2024
Merger
10<1
Jul 05, 2024
Merger
10<1
